Adam Sperling, MD, PhD
@adamssperling.bsky.social
Physician scientist UCLA --> BWH <--> DFCI —> Stanford. Myeloma, CAR-T, CHIP, MDS.
Congratulations to Dr. Hermann Einsele and Dr. Noopur Raje, who will be honored today for their extraordinary contributions to myeloma at the 2026 IMWG Summit in Stockholm, Sweden. Learn more: https://www.myeloma.org/node/12929 #IMFIMWG
Let’s do some discourse. Who has the best breakfasts? My vote is Mexico: huevos rancheros/divorciados, chilaquiles, molletes, tetelas, papas con chorizo, churros, migas… plus café de olla I dunno, I think they figured it out?
Beautiful work and congratulations on starting your own lab. Look forward to seeing what you’ll do and hope we can work together again in the future.
Jonas Koeppel@jonaskoeppel.bsky.social · 2mo ago22/n On a personal note, I’ll soon start an independent research group in the Genome Biology Unit at EMBL Heidelberg. If you enjoy this type of work and want to engineer genomes at the largest scale, please reach out! jonas-koeppel.github.io/koeppellab/ www.embl.org/groups/koepp...
A rapid manufacturing pipeline for BCMA-targeting CAR T cells drastically shortens “vein-to-vein” times, and produces cells that demonstrate encouraging safety results in a phase one trial of patients with relapsed #MultipleMyeloma. #ScienceTranslationalMedicine https://scim.ag/4fd3JaW
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.
scim.ag
Excited that our paper describing a phase 1 trial of ducabtagene autloeucel, a rapidly manufactured anti-BCMA CAR-T in r/r multiple myeloma, was published. #ScienceTranslationalMedicine Huge thanks to all my co-authors, the teams at @danafarber.bsky.social and Novartis, and to our patients.
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.
science.org
Registration is open for #IMS26! Secure your spot now and join your colleagues in Glasgow ➡️ http://bit.ly/4cdFJkH
Congrats on getting this up and running. Will be an incredible resource for patients and clinicians.
Jonathan Keats, PhD 🇨🇦@pedalheadphx.bsky.social · 3mo agoAfter largely running our clinical whole genome sequencing test for #myeloma, JAYseq, in stealth mode for the last 6 months I am extremely proud to see the culmination of years of research effort by my team at TGen and collaborators around the world come to fruition in a clinical test.
At #AACR26: Results from CAR-PRISM Trial. Dr. Omar Nadeem says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration." @danafarber.bsky.social ➡️ bit.ly/4tmxcmW
We are actively recruiting a postdoctoral fellow to join our lab @jacksonlab! 😎 Details and link to apply: thejacksonlaboratory.wd503.myworkdayjobs.com/External_JAX...
Postdoctoral Associate
Postdoctoral Associate Trowbridge Lab Bar Harbor, ME A Postdoctoral Associate position is available in Dr. Jennifer Trowbridge’s laboratory at The Jackson Laboratory in Bar Harbor, Maine. The Trowbrid...
thejacksonlaboratory.wd503.myworkdayjobs.com
After a fantastic MGR today, we are thrilled to welcome Dr. Ross Levine back for our #hematology seminar tomorrow - very thankful to Ross for such & engaging & fun visit! #MPNsm @stanforddeptmed.bsky.social @rosslevinemd.bsky.social @mskcancercenter.bsky.social
Stanford Hematology Division@stanford-heme.bsky.social · 4mo ago✨Thrilled to welcome the esteemed Dr. Ross L. Levine for a captivating presentation at the Breakthroughs in Hematology seminar tomorrow!✨ @rosslevinemd.bsky.social @stanforddeptmed.bsky.social l @mskcancercenter.bsky.social
Congratulations to Irene Ghobrial, MD, recipient of Senior Researcher Prize of the Francesca Cassinelli Award for 2025. The award recognizes Ghobrial's exceptional scientific excellence, international leadership, and impactful contributions to multiple myeloma. Learn more: bit.ly/4cFHFV4
Ohh, awesome! I was actually wondering about this exact thing recently. It's super helpful to have data to answer the question.
Jennifer Trowbridge@trowbridgelab.bsky.social · 5mo agoInstitutions are phasing out gamma-irradiators, but can X-ray irradiators replace them for mouse transplant models? We report that with proper dose calibration, X-ray conditioning produces equivalent hematopoietic chimerism and AML transplant outcomes. Encouraging news! 🔗 doi.org/10.1016/j.ex...
We are profoundly grateful to announce the largest single gift in our 78-year history through a new joint commitment from Josh and Anita Bekenstein and the Jonathan Lavine and Jeannie Lavine family.
Very important new paper by Samur et al on SMM in JCO - will change our thinking! @pedalheadphx.bsky.social @myeloma-society.bsky.social @themmrf.bsky.social @imfmyeloma.bsky.social @szusmani.bsky.social # ascopubs.org/doi/10.1200/...
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
PURPOSEThe diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early ...
ascopubs.org
@paralkarlab.bsky.social Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at @mdanderson.bsky.social for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS. www.biorxiv.org/content/10.1...
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...
biorxiv.org
Journalist here I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04 Reposts are appreciated!
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more: bit.ly/4pRWiZy
Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀 Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com 📄 www.nature.com/articles/s41... 🧵1/n
Rapid epigenomic classification of acute leukemia - Nature Genetics
The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.
nature.com
Dr. Rashidian from @danafarbernews.bsky.social presenting his work at the 2025 @myeloma-society.bsky.social meeting.
Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more: bit.ly/45wiiQ6
Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute
Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.
bit.ly
The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova , @ernstlaboratory.bsky.social @steidluli.bsky.social @ericpietras.bsky.social @kathrinbernt.bsky.social @gritsmanlab.bsky.social
And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
urldefense.proofpoint.com